Literature DB >> 21931090

Reconstruction of complex nasal dorsal and sidewall defects: is the nasal sidewall subunit necessary?

Thorsen W Haugen1, John L Frodel.   

Abstract

OBJECTIVE: To demonstrate that by the extended use of cheek advancement flaps, the need to maintain the nasal dorsal side unit is obviated.
DESIGN: Retrospective case series.
SETTING: Tertiary care clinic and hospital. PATIENTS: Twelve patients aged 48 to 88 years who underwent Mohs micrographic surgery for nasal skin neoplasms, presenting with dorsal sidewall and nasal dorsal cutaneous defects. INTERVENTION: All patients underwent nasal reconstruction with adjacent tissue cheek advancement flaps with or without contralateral nasal dorsal and sidewall advancement flaps. MAIN OUTCOME MEASURES: Avoidance of ipsilateral nasal sidewall scars to allow a natural-appearing transition between the cheek and nose and avoidance of forehead flap morbidity. Results Satisfactory results were achieved in all but 1 patient who had partial flap necrosis.
CONCLUSIONS: To maintain the nasal dorsal sidewall unit, superior, central dorsal, and nasal sidewall defects have traditionally been reconstructed using a variety of techniques, including skin grafts and regional flaps, such as glabellar flaps and frontal flaps. We demonstrate that creation of the nasal dorsal sidewall unit is often not necessary, and excellent results can be achieved through the expanded use of cheek advancement flaps.

Entities:  

Mesh:

Year:  2011        PMID: 21931090     DOI: 10.1001/archfacial.2011.51

Source DB:  PubMed          Journal:  Arch Facial Plast Surg        ISSN: 1521-2491


  2 in total

1.  Versatility of advancement flaps for nasal reconstruction following Mohs` micrographic surgery.

Authors:  Felipe Bochnia Cerci
Journal:  An Bras Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.896

2.  Bilateral superiorly based malar transposition flaps for nasal tip reconstruction: A case report.

Authors:  David B Roy; Paarth Dodia; Michael Roberts
Journal:  SAGE Open Med Case Rep       Date:  2021-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.